Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1021/acsinfecdis.0c00052 http://scihub22266oqcxt.onion/10.1021/acsinfecdis.0c00052 32125140!7098069!32125140     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32125140&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 500 Internal Server Error in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       ACS+Infect+Dis 2020 ; 6 (5): 909-915 Nephropedia Template TP {{tp|p=32125140|t=2020. Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential |pdf=|usr=}}{{32125140}} gab.com Text Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential JO: ACS Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32125140 #FOAvip The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19. Twit Text FOAVip Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential ????ACS Infect Dis http://www.kidney.de/pget.php?&tw=1&pmid=32125140 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32125140 #FOAvip English Wikipedia <ref>{{Cite pmid|32125140}}</ref> Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potential #MMPMID32125140 Xu J; Shi PY; Li H; Zhou J ACS Infect Dis 2020[May]; 6 (5): 909-915 PMID32125140show ga The recent outbreak of coronavirus disease 2019 (COVID-19) highlights an urgent need for therapeutics. Through a series of drug repurposing screening campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to be effective against various viral infections with nanomolar to micromolar potency such as SARS-CoV, MERS-CoV, ZIKV, HCV, and human adenovirus, indicating its potential as an antiviral agent. In this brief review, we summarize the broad antiviral activity of niclosamide and highlight its potential clinical use in the treatment of COVID-19. |*Drug Repositioning[MESH] |Antiviral Agents/*pharmacology[MESH] |Betacoronavirus/drug effects[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Coronavirus Infections/*drug therapy[MESH] |Humans[MESH] |Middle East Respiratory Syndrome Coronavirus/drug effects[MESH] |Niclosamide/*pharmacology[MESH] |Pandemics[MESH] |Pneumonia, Viral/*drug therapy[MESH] |SARS-CoV-2[MESH]Broad Spectrum Antiviral Agent Niclosamide and Its Therapeutic Potenti(epmc).pdf DeepDyve Pubget Overpricing